Visit
Topline data has been released from Eli Lilly and Company showing that donanemab significantly slowed cognitive decline by 35% and…
On January 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab for the treatment of Alzheimer’s disease (AD),…
New data published in the Journal of Alzheimer’s disease suggest that the loss of soluble Aβ42 predicts cognitive decline better…
The Phase III, multicenter, randomized EXERT trial enrolled almost 300 patients to investigate the effects of regular exercise on brain…
The U.S. Food and Drug Administration (FDA) has authorized the marketing of the Fujirebio’s Lumipulse G β-Amyloid Ratio (1-42/1-40) in…
An exciting study published in Nature Genetics has doubled the number of genetic loci known to associate with Alzheimer’s disease,…
The Alzheimer’s Research UK Conference was held in Brighton, UK, on 1-2 March 2022. Leading experts discussed the key topics…
In recent years, there has been a greater interest in gaining further insight into the relationship between Alzheimer’s disease (AD)…
Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…
A hallmark feature of Alzheimer’s disease (AD) is the aggregation of amyloid-β (Aβ). Although many trials have been conducted aiming…
